A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein

Journal of Immunology

Volumn 171, Issue 1, 2003, Pages 219-225

  Zhang, Yi ^a   Chaux, Pascal ^a,e   Stroobant, Vincent ^a   Eggermont, Alexander M M ^b   Corthals, Jurgen ^c   Maillère, Bernard ^d   Thielemans, Kris ^c   Marchand, Marie ^a   Boon, Thierry ^a   Van der Bruggen, Pierre ^a,f  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d CEA SACLAY   (France)

^e Oncodesign SA   (France)

^f LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HLA DR1 ANTIGEN; MELANOMA ANTIGEN 3; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; GERM LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN ISOLATION; T LYMPHOCYTE ACTIVATION; TISSUE SPECIFICITY; VACCINATION;

EID: 0037530637     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.1.219     Document Type: Article

References (27)

1. Boon, T., J.-C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337.
2. van der Bruggen, P., Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E. S. Schultz, J. Chapiro, B. J. Van den Eynde, F. Brasseur, and T. Boon. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188:51.
3. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dréno, M.-H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219.
4. Coulie, P. G., V. Karanikas, C. Lurquin, D. Colau, T. Connerotte, T. Hanagiri, A. Van Pel, S. Lucas, D. Godelaine, C. Lonchay, et al. 2002. Cytolytic T cell responses of cancer patients vaccinated with a MAGE antigen. Immunol. Rev. 188:33.
5. Thumer, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P, von den Driesch, et al. 1999. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669.
6. + melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 165:3492.
7. Schuler-Thurner, B., E. S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, and G. Schuler. 2002. Rapid induction of tumor-specific type I T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195:1279.
8. Marchand, M., C. J. A. Punt, S. Aamdal, B. Escudier, W. H. J. Kruit, U. Keilholz, L. Håkansson, N. van Baren, Y. Humblet, P. Mulders, et al. 2003. Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: clinical report. Eur. J. Cancer 39:70.
9. Baldo, M., M. Schiavon, P. A. Cicogna, P. Boccato, and F. Mazzoleni. 1992. Spontaneous regression of subcutaneous metastasis of cutaneous melanoma. Plast. Reconstr. Surg. 90:1073.
10. Altman, J. D. P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams. J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
11. Coulie, P. G., V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard, and T. Boon. 2001. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA 98:10290.
12. + cytolytic T lymphocytes. Cancer Res. 60:6272.
13. + T lymphocytes. J. Exp. Med. 189:767.
14. Mavilio, F., G. Ferrari, S. Rossini, N. Nobili, C. Bonini, G. Casorati, C. Traversari, and C. Bordignon. 1994. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 83:1988.
15. Schultz, E. S., J. Chapiro, C. Lurquin, S. Claverol, O. Burlet-Schiltz, G. Warnier V. Russo, S. Morel, F. Levy, T. Boon, B. J. Van den Eynde, and P. van der Bruggen. 2002. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med. 195:391.
16. Genevée, C., A. Diu, J. Nierat, A. Caignard, P. Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22:1261.
17. Texier, C., S. Pouvelle, M. Busson, M. Herve, D. Charron, A. Menez, and B. Maillere. 2000. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164:3177.
18. Texier, C., S. Pouvelle-Moratille, M. Busson, D. Charron, A. Menez, and B. Maillere. 2001. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31:1837.
19. Sanderson, S., K. Frauwirth, and N. Shastri. 1995. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc. Natl. Acad. Sci. USA 92:7217.
20. Roche, P. A., and P. Cresswell. 1990. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J. Immunol. 144:1849.
21. + T cell responses. J. Immunol. 163:5820.
22. + T cells. Eur. J. Immunol. 31:1910.
23. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189:871.
24. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588.
25. Natali, P., A. Bigotti, R. Cavalieri, M. R. Nicotra, R. Tecce, D. Manfredi, Y. X. Chen, L. M. Nadler, and S. Ferrone. 1986. Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin. Hum. Immunol. 15:220.
26. Taramelli, D., G. Fossati, A. Mazzocchi, D. Delia, S. Ferrone, and G. Parmiani. 1986. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res. 46:433.
27. + T cells. J. Immunol. Methods 268:71.